Medicxi company information, Employees & Contact Information

Adjuvant Capital Joins $110 Million Series B For Curevo citybiz

J&J and GSK Join Medicxi Ventures CHEManager

Sofinnova and Medicxi talk M&A, patent cliffs, and China BioXconomy

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder PR Newswire Canada

Medicxi Announces $400m Medicxi IV FirstWord Pharma

UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech Labiotech.eu

European VC Medicxi raises $400M for ‘asset-centric’ biotech investing BioPharma Dive

Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome GlobeNewswire

Medicxi rakes in $400M for 'deliberately sized' 4th life sciences fund Fierce Biotech

Vaderis Therapeutics AG Emerges from Stealth and Announces Initiation of Clinical Proof-of-Concept Trial in HHT PR Newswire

Medicxi combines 6 portfolio orgs with $100M seed to launch derm company Medical Marketing and Media

Medicxi announces $400M fund for life science companies Labiotech.eu

D3 Bio Completes Series A+ Round to Advance Innovative Oncology Pipeline PR Newswire

Medicxi turns six into one, with launch of new immuno-dermatology firm FirstWord Pharma

Meet this Blockbuster Developer turned Partner at a Headlining VC Labiotech.eu

On the heels of $250M launch, Centessa barges ahead with an IPO to fuel its 10-in-1 Medicxi pipeline Endpoints News

Medicxi Combines Six Portfolio Companies with $100M to Launch Alys Pharma BioSpace

Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody Business Wire

Centessa 2.0 with a twist: Medicxi combines six immuno-derm startups with $100M Endpoints News

Medicxi-backed Vicebio: vaccines with stability, production advantages BioCentury

Novartis, Verily back $300M Medicxi biotech growth fund Fierce Biotech

10 biotechs become 1: Centessa launches with $250M to prove unorthodox R&D model BioPharma Dive

Alys Pharmaceuticals: $100 Million Financing Raised From Medicxi Pulse 2.0

Medicxi unveils Monopteros with $20M, mission to reprogram T cells Fierce Biotech

Palladio grabs $20M to take once-discarded drug through phase 3 Fierce Biotech

Biotech-focused Medicxi forges separate dynasty Venture Capital Journal

Sosei spins out 2 CNS companies with help from Medicxi Fierce Biotech

Rivus Pharmaceuticals Launches with $35 Million Series A Financing to Develop Novel Treatments for Cardio-Metabolic Diseases PR Newswire

Medicxi forms Alys Pharma with six dermatology-focused companies with $100m PMLiVE

Keytruda keeps expanding with another priority review; Medicxi-backed eye drop maker wins new funding, regional deal Endpoints News

SutroVax Announces $85M Series C Financing led by TPG Growth PR Newswire

One year after leaving GSK, Emmanuel Hanon jumps to Medicxi-backed vaccine startup with an eye on RSV Endpoints News

Slaoui apologizes 'unreservedly' after sexual harassment allegations prompt biotechs to part ways Fierce Pharma

Medicxi launches asset-centric Centessa by acquiring 10 companies BioWorld MedTech

Medicxi put €40m into two Sosei spin off companies European Biotechnology Magazine

Australia's Starpharma and UK-based Medicxi create Petalion Therapeutics to develop novel dendrimer-based treatments BioSpectrum Asia

Travers Smith advises Medicxi on Centessa Pharmaceuticals Travers Smith

Starpharma partners with UK investment firm to create Petalion Therapeutics BiotechDispatch

Medicxi Ventures Closes First Life Sciences Fund, at €210M FinSMEs

Trump Taps Ex-Glaxo Official and General to Lead Vaccine Race Bloomberg.com

Elian appointed to provide fund administration services to Medicxi Ventures’ first €210m fund Bailiwick Express